Synaptogenix launches crypto treasury strategy focused on Bittensor TAO, raises $5.5M

TAO Synergies Inc.

Plans initial $10M acquisition of TAO tokens (over 2x market cap); long-term target of $100M.
Raised $5.5M via private placement of Series D convertible preferred stock ($1,000 stated value) and warrants at $3.00 per share.
James Altucher hired as consultant to lead TAO strategy; issued 1.2M warrants with exercise prices from $4.00 to $12.00.
CEO Dr. Tuchman resigned to become CMO; CSO Dr. Alkon resigned to consultant; Joshua Silverman appointed Executive Chairman at $30k/month.
Company intends to change name and ticker to reflect new digital asset treasury strategy.

item 1.01 item 3.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Alan J. Tuchman

Chief Executive Officer

TAOX · TAO Synergies Inc.

Effective: 2025-06-08
Filed: June 9, 2025, 7:59 PM ET

On June 8, 2025, Dr. Alan J. Tuchman resigned as Chief Executive Officer and director of the Company, effective June 8, 2025. Dr. Tuchman will serve as Chief Medical Officer of the Company.

Departed

Daniel L. Alkon

Chief Science Officer

TAOX · TAO Synergies Inc.

Effective: 2025-06-04
Filed: June 9, 2025, 7:59 PM ET

On June 4, 2025, Dr. Daniel L. Alkon resigned as an officer, director and Chief Science Officer of the Company to become a consultant working with the Company’s newly established Bryostatin Development Committee

Appointed

Joshua Silverman

Executive Chairman

TAOX · TAO Synergies Inc.

Effective: 2025-06-06
Filed: June 9, 2025, 7:59 PM ET

On June 6, 2025, Mr. Joshua Silverman was appointed as Executive Chairman of the Company’s board of directors and in consideration of his new role, Mr. Silverman will be paid a monthly salary of $30,000 per month.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alan J. Tuchman resigned as Chief Executive Officer at TAO Synergies Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On June 8, 2025, Dr. Alan J. Tuchman resigned as Chief Executive Officer and director of the Company, effective June 8, 2025. Dr. Tuchman will serve as Chief Medical Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel L. Alkon resigned as Chief Science Officer at TAO Synergies Inc..

Action: resigned
Role: Chief Science Officer

Exact text from the filing

On June 4, 2025, Dr. Daniel L. Alkon resigned as an officer, director and Chief Science Officer of the Company to become a consultant working with the Company’s newly established Bryostatin Development Committee

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua Silverman was appointed as Executive Chairman at TAO Synergies Inc..

Action: appointed
Role: Executive Chairman

Exact text from the filing

On June 6, 2025, Mr. Joshua Silverman was appointed as Executive Chairman of the Company’s board of directors and in consideration of his new role, Mr. Silverman will be paid a monthly salary of $30,000 per month.

View on SEC.gov

TAO Synergies Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-057640

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.